沙利度胺辅助化疗治疗老年多发性骨髓瘤中的可行性分析

摘要

Objective:To investigate the feasibility of thalidomide combined with chemotherapy in the treatment of elderly in multiple myeloma.Methods:60 elderly patients with multiple myeloma were selected from March 2012 to March 2014.They were randomly divided into the control group and the observation group.The control group were mainly given VAD chemotherapy treatment,and the observation group were given thalidomide treatment based on the control group,and we observed the therapeutic effect of the two groups patients.Results:The remission rate of the observation group (86.67%) was higher than that of the control group(60%)(P<0.05),and after the treatment,the blood M protein,bone marrow plasma cell number of the observation group were significantly lower than those of the control group(P<0.05),Hemoglobin and Karnofsky scores were significantly higher than those of the control group(P<0.05).Conclusion:The effect of thalidomide combined with chemotherapy in the treatment of elderly patients with multiple myelomat is remarkable,and the feasibility is high,so it is worth for clinical use.%目的：探讨沙利度胺辅助化疗治疗老年多发性骨髓瘤中的可行性。方法：2012年3月-2014年3月收治老年多发性骨髓瘤患者60例，随机分为对照组和观察组，对照组主要采用VAD化疗方案治疗，观察组在对照组治疗的基础上实施沙利度胺治疗，并观察两组患者治疗效果。结果：观察组缓解率86.67%高于对照组的60.0%(P＜0.05)，同时治疗后观察组的血M蛋白、骨髓浆细胞数均显著低于对照组(P＜0.05)，血红蛋白、Karnofsky评分均显著高于对照组(P＜0.05)。结论：沙利度胺辅助化疗治疗老年多发性骨髓瘤效果显著，可行性高，值得临床推广使用。